The significant impacts of lipid-lowering medications, such as HMG-CoA reductase inhibitors, in ameliorating neurological outcomes and lowering stroke incidence in various patient categories, including those with coronary heart disease, DM and HTN, as well as the elderly, were previously reported [54–57]. The gene discussed is HMGCR; the disease is coronary artery disorder.